Nimodipine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nimodipine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Decreased blood pressure | 0% |
| Abnormal liver function test | 0% |
| Edema | 0% |
| Diarrhea | 0% |
| Rash | 0% |
| Headache | 0% |
| Gastrointestinal symptoms | 0% |
| Nausea | 0% |
| Dyspnea | 0% |
| Ekg abnormalities | 0% |
| Tachycardia | 0% |
| Bradycardia | 0% |
| Muscle pain/cramp | 0% |
| Acne | 0% |
| Depression | 0% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Source: FDA labeling via NIH DailyMed (set e65d5108…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.